INTRODUCTION {#sec1}
============

Channelopathy disorders are caused by the abnormal functioning of ion channel subunits ([@B20]; [@B29]). The leading sources of channel dysfunction are de novo and inherited nucleotide changes, which can be classified as gain- or loss-of-function (GOF, LOF) mutations. GOF mutations alter channel activity in a way that increases current magnitude or duration, whereas LOF produces the opposite effect, to reduce current size or duration. Both types of mutations have been found in the *KCNMA1* gene ([@B1]), which encodes the pore-forming α-subunit of the "Big K^+^" (BK) calcium- and voltage-activated channel ([@B11]; [@B27]; [@B33]). For the majority of *KCNMA1* mutations, it has not yet been established how the genetic changes alter BK channel function and under which conditions these alterations manifest ([@B1]).

BK channels have a characteristically large conductance (100--270 pS) ([@B22]) and a highly K^+^-selective pore. The channel is a homotetramer of four BKα subunits encoded by the *KCNMA1* gene ([@B28]; [@B37]). Each BKα subunit comprises seven transmembrane segments (TM0--TM6) and a large intracellular COOH terminus ([Fig. 1*A*](#F0001){ref-type="fig"}) ([@B28]). Within these regions, three domains are essential to activate and regulate channel activity. The voltage-sensing domain (VSD), located between TM1 and TM4, controls depolarization-dependent activation ([@B19]; [@B38]). The COOH-terminal domain, called the "gating ring," houses the regulators of K^+^ conductance domains (RCK1 and RCK2). Each RCK domain contains one high-affinity Ca^2+^-binding site, which enables channel opening in response to increases in intracellular Ca^2+^ ([@B17]; [@B39]; [@B48]). The third domain is the accessory subunit binding interface formed by the NH~2~ terminus and TM0, which is necessary for interaction with the accessory beta (β1--4) and/or gamma (γ1−4) subunits ([@B31]; [@B44]). Altogether, these three domains work together allosterically to open the pore gating domain (PGD) located between TM5 and TM6 and allow the K^+^ efflux from the cell ([@B18]; [@B23]).

![Wild-type (WT) and N999S BK channel properties in symmetrical K^+^ and 1 μM Ca^2+^. *A*: schematic representation of 1 BKα subunit, with the extracellular NH~2~ terminus, 7 transmembrane segments (TM0--TM6), and the intracellular COOH terminus containing the Ca^2+^ binding sites. Black, voltage sensor domain (VSD); gray, RCK1 and RCK2 domains comprising the gating ring. Dark gray circles correspond to the calcium binding sites, Gray dotted line between TM6 and RCK1 calcium binding site corresponds to AC region. Relative positions for the mutations D434G \[13 known patients ([@B1]; [@B10])\], N999S \[7 known patients ([@B1]; [@B25]; [@B53])\], and R1128W \[1 patient known ([@B16])\] are shown. The only patient carrying the mutation R1128W additionally harbors the N999S mutation. *B*: representative macroscopic currents at 20-mV increments with the voltage-step protocol applied. *C*: conductance-voltage (*G-V*) relationship for WT (*n* = 7) and N999S (*n* = 6) channels. *G* was normalized to the highest conductance calculated (*G*~max~). The *G-V* curves fit with a Boltzmann function (solid line). *D*: half-maximal voltage of activation (*V*~1/2~) values for WT and N999S channels (\*\*\*\**P* \< 0.0001, 1-way ANOVA, Tukey post hoc test). *E*: activation time constant (τ~act~) vs. voltage for WT (*n* = 7) vs. N999S (*n* = 6). *Insets* show representative activation traces of both channels at +160 and +240 mV (the scale is the same for both). N999S shows significantly faster activation between +120 and +170 mV (*P* \< 0.05, 2-way repeated-measures ANOVAs with Bonferroni post hoc) but not between −180 and +250. *F*: deactivation time constant (τ~deact~) for WT (*n* = 4) and N999S (*n* = 5) channels. N999S shows significantly slower deactivation kinetics compared with WT (*P* \< 0.05 at −60 to −100, 2-way repeated-measures ANOVAs with Bonferroni post hoc). *Inset* illustrates representative portion of the tail currents at −60 mV (2 s of the total 20-s deactivation protocol).](z9k0022053530001){#F0001}

Gating by voltage and Ca^2+^ confers specialized regulation of membrane potential in excitable cells. BK channels are expressed widely in neurons and muscle, where they exert specific effects on membrane potential through different splice variants, interactions with accessory subunits, and coupling to Ca^2+^ sources ([@B5]; [@B12]; [@B15]; [@B21]). This selective tuning of BK channel properties through different molecular mechanisms and protein interactions produces distinct functional consequences for excitability. In the brain, the BK channel performs dual roles in regulating excitability depending on neuronal type ([@B6]; [@B30]). For example, BK channel activation can either deaccelerate (Purkinje neurons) or speed (GABAergic neurons) action potential (AP) firing, and therefore modulate neurotransmitter release ([@B6]; [@B21]; [@B42]). Thus BK channels manifest their pivotal role in preventing transmitter-related hyperexcitability, and therefore neuronal dysfunction, through this balance of activity ([@B3]).

Since the identification of the first disease-linked *KCNMA1* mutation ([@B10]), the number of patients identified with neurological disorders and mutations in BK channels has increased ([@B1]). Of the *KCNMA1* mutations currently known, only two are confirmed GOF with respect to their effects on BK channel activity, D434G and N999S (also identified as N995S and N1053S; [@B1]; [@B10]; [@B25]; [@B53]). These two mutations are located in the COOH-terminal gating ring ([Fig. 1](#F0001){ref-type="fig"}) and share a phenotypic association with epilepsy and/or paroxysmal nonkinesigenic dyskinesia (PNKD). The D434G mutation was identified in 13 related family members ([@B10]), and the N999S mutation was found in 4 unrelated patients as a de novo mutation ([@B25]; [@B47]; [@B53]). Despite the GOF nature of both *KCNMA1* mutations, only the D434G mutation has been extensively biophysically characterized, whereas the N999S mutation has been studied in a more limited set of membrane conditions ([@B8]; [@B10]; [@B25]; [@B47]; [@B53]).

In this study, we characterized the effects of the mutation N999S and the novel double mutation N999S/R1128W found in one patient ([@B16]) in the context of a brain-expressed *KCNMA1* splice variant ([@B36]), under physiological K^+^ and Ca^2+^ conditions. Additionally, we compared the BK currents from channels containing the N999S or the D434G mutation to improve the understanding of the distinction between BK channel GOF mutations. Thus this study provides additional evidence for the changes in the BK channel's biophysical properties induced by the N999S mutation, confirming its GOF nature in a different splice variant than previously characterized, in tandem with a second patient mutation, and in a new set of physiologically relevant ionic and stimulus paradigm conditions.

METHODS {#sec2}
=======

The mutations N999S (rs886039469), N999S/R1128W (rs747029218), and D434G (rs137853333) were introduced by site-directed mutagenesis into the WT human *KCNMA1* (BK channel) cDNA sequence ([MG279689](https://www.ncbi.nlm.nih.gov/nuccore/1480118271)) in the pcDNA3.1+ mammalian expression vector. All mutations were verified by sequencing. Channel constructs contained an NH~2~-terminal extracellular Myc tag and enhanced yellow fluorescent protein (EYFP) in RCK2, used to identify transfected cells. Wild-type (WT) and mutant channel plasmids were transfected into HEK293T cells as previously described ([@B36]), and electrophysiological recordings were performed 14--24 h after transfection.

BK currents were recorded in inside-out patch-clamp configuration at 22--24°C ([@B36]). For symmetrical K^+^ recordings, electrodes (2--3 MΩ) were filled with (in mM) 140 KMeSO~3~, 2 KCl, 2 MgCl~2~, and 20 HEPES. The internal (bath) solution contained (in mM) 140 KMeSO~3~, 2 KCl, 20 HEPES, and 5 HEDTA with 1 μM CaCl~2~ (pH adjusted to 7.2 with KOH). In physiological K^+^ recordings, electrodes contained (in mM) 134 NaCl, 6 KCl, 1 MgCl~2~, 10 glucose, and 10 HEPES (pH 7.4 with NaOH). The internal (bath) solution contained (in mM) 110 KMeSO~3~, 10 NaCl, 30 KCl, 10 HEPES, 1 MgCl~2~, and 5 HEDTA with 10 µM CaCl~2~ (pH 7.2 with KOH). Free Ca^2+^ concentrations were calculated with WebMaxC (<https://somapp.ucdmc.ucdavis.edu/pharmacology/bers/maxchelator/webmaxc/webmaxcS.htm>).

Voltage commands were applied with a MultiClamp700B amplifier, Digidata1440, and Clampex v10.3 (Molecular Devices, Sunnyvale, CA). Macroscopic BK current traces were acquired at 50 kHz and filtered online at 10 kHz. Current parameters were analyzed in pCLAMP 10.6 (Molecular Devices). In each set of experimental conditions, two different voltage-step protocols were used. The first protocol was used to generate the conductance-voltage (*G-V*) relationship, the half-maximal voltage of activation (*V*~1/2~), and activation kinetics. The second protocol was applied to obtain deactivation kinetics. In symmetrical K^+^-1 μM Ca^2+^ experiments, the voltage activation protocol stepped from a holding potential (*V*~hold~) of −100 mV to +250 mV (Δ +10-mV increments) for 30 ms and back to −100 mV for 15 ms to generate tail currents. In physiological K^+^-10 μM Ca^2+^ experiments, the protocol stepped from a *V*~hold~ of −150 mV to +150 mV (Δ +10-mV increments) for 30 ms and back to −150 mV for 15 ms to generate tail currents. *G* was calculated from tail currents, 150--200 µs after the peak, normalized to the highest conductance calculated for each patch (*G*/*G*~max~), and plotted against membrane potential (*V*) to generate conductance-voltage (*G*/*G*~max~-*V*) curves. *V*~1/2~ values were calculated from a Boltzmann fit of the *G*/*G*~max~-*V* relationship (Prism v8.2.0; GraphPad Software, San Diego, CA). Activation time constants (τ~act~) were obtained from the same voltage activation protocol by fitting a single standard exponential to the rising phase of the outward K^+^ current. The protocol used to determine the deactivation time constant (τ~deact~) was the same in both ionic conditions: BK currents were activated by a +200-mV voltage step for 20 ms, from −150 mV (*V*~hold~), followed by 15-ms voltage steps from −200 mV to −50 mV (Δ +10-mV increments). Deactivation kinetics were measured by fitting tail currents with single-exponential functions. In all protocols, leak current was subtracted with a P/5 protocol with a subsweep *V*~hold~ of −120 mV ([@B36]). A third voltage protocol was used in the physiological K^+^-10 μM Ca^2+^ condition to evoke AP-activated BK currents. This protocol consisted of a representative neuronal AP waveform as a voltage command ([@B36]). BK current was measured at the peak of the AP command and normalized to the maximum steady-state current evoked by a standard voltage activation protocol (between +70 and +100 mV).

Acetazolamide (ACTZ) (catalog no. A6011; Sigma-Aldrich) experiments were performed in physiological K^+^-10 μM Ca^2+^ solutions. The voltage protocol consisted of a 30-ms activation step, from −150 mV (*V*~hold~) to the *V*~1/2~ for either WT or N999S channels, 60 times at 5-s intervals. After a 1-min baseline, 50 μM ACTZ (in DMSO) was added and, 3 min later, 100 nM paxilline (catalog no. 2006; Tocris, Bristol, UK). Steady-state BK current levels were plotted over time before and after drug application.

Statistical analysis was performed in Prism v8.2 (GraphPad) and consisted of one-way ANOVA with Tukey post hoc test (*V*~1/2~ values and normalized AP-evoked comparisons), repeated-measures ANOVA with Bonferroni post hoc (activation/deactivation kinetics), and paired *t* tests (before/after ACTZ). All data in figures are presented as means ± SE, with individual data points superimposed for *V*~1/2~ and AP values.

RESULTS {#sec3}
=======

 {#sec3-1}

### GOF properties of N999S channels. {#sec3-1-1}

Because of the lack of a BK channel splice variant with known physiological function cloned from human tissue, in this study the effects of WT and patient *KCNMA1* mutations were examined within the context of a brain variant cloned from mouse hypothalamus that was humanized ([MG279689](https://www.ncbi.nlm.nih.gov/nuccore/1480118271)) ([@B36]). The alternative exons contained within the gating ring are SRKR (RCK1/site 1), no exon (STREX/site 2), 27-aa exon (Ca^2+^ bowl/site 3), and the COOH-terminal exon RKEMVYR ([@B34]; [@B36]), similar to human variant [NM_001322835](https://www.ncbi.nlm.nih.gov/nuccore/1675072664). This BK variant also contains an extracellular NH~2~-terminal Myc tag and EYFP in RCK2. Currents from this BK channel variant with and without these tags were similar ([@B34]).

To evaluate the effect of the N999S mutation on BK current properties, we recorded from inside-out patches from HEK293T cells transfected with WT or N999S channels. In neurons, the activation of BK is driven by the combination of voltage and an increase in intracellular Ca^2+^ level, and these experiments were therefore performed in the presence of 1 μM intracellular Ca^2+^ ([@B49]). With a voltage-clamp protocol of square depolarizing voltage steps, the currents from N999S channels were compared to WT channels across a range of voltages from −100 to 250 mV ([Fig. 1*B*](#F0001){ref-type="fig"}).

The normalized conductance-voltage (*G-V*) relationships were compared, which allows assessment of the relative voltage dependence of activation for mutant versus WT channels, as well as the kinetics of opening and closing. N999S channels were more sensitive to membrane depolarization ([Fig. 1*C*](#F0001){ref-type="fig"}). The voltage of half-maximal activation (*V*~1/2~) for N999S currents was shifted to more hyperpolarized potentials by 55 mV compared with WT (N999S: +78 ± 1.5 mV and WT: +133 ± 1.7 mV; [Fig. 1*D*](#F0001){ref-type="fig"}). However, no significant differences in the *G-V* slope were observed (WT *z* = 0.8 ± 0.01 vs. N999S *z* = 0.9 ± 0.07; *P* = 0.086, unpaired *t* test), suggesting that WT and N999S channel activations have similar voltage sensitivity.

Analysis of activation kinetics (τ~act~) between +120 and +170 mV showed a faster N999S activation than WT ([Fig. 1*E*](#F0001){ref-type="fig"}, *inset* at +160 mV). This difference is mediated by the shifted voltage dependence of N999S channels, which is 55 mV more hyperpolarized than WT, and can be demonstrated by analyzing voltages corrected for the *V*~1/2~ (τ~act~ at 120 mV, WT = 7.4 ± 1.5 and N999S = 8.04 ± 1.04; *P* = 0.25). Between +180 and +250 mV, where the channels are maximally open, the activation kinetic values between the currents were not different ([Fig. 1*E*](#F0001){ref-type="fig"}, *inset* at +240 mV). Contrary to what was observed with activation, N999S channels close slower (τ~deact~) across all voltages compared with WT. Between −60 and −100 mV, τ~deact~ values for N999S currents were \~5 times slower than those for WT ([Fig. 1*F*](#F0001){ref-type="fig"}). Taking these data together, the changes in BK current establish that the N999S mutation confers GOF properties to a brain-expressed BK channel variant, producing larger BK currents that activate at lower voltages because of the shifted *V*~1/2~ and activate faster and deactivate slower than WT.

We next studied the N999S GOF phenotype in physiological Na^+^ and K^+^ gradients and 10 μM intracellular Ca^2+^ conditions, which mimics the K^+^-driving force on channel activation and intracellular Ca^2+^ levels during some types of neuronal activity ([Fig. 2*A*](#F0002){ref-type="fig"}). Because the BK channel is coupled to voltage-gated Ca^2+^ channels (Ca~v~) in neurons, 10 μM Ca^2+^ is the estimated average activating concentration during an AP ([@B13]; [@B26]). N999S currents showed a 46-mV shift in the *V*~1/2~ toward negative potentials compared with WT in response to the protocol of depolarizing voltage steps (*V*~1/2~ values: N999S −8 ± 4.2 mV and WT +38 ± 1.4 mV; [Fig. 2](#F0002){ref-type="fig"}, *B* and *C*). Thus N999S channels are significantly more active at more hyperpolarized potentials compared with WT, resulting in larger outward K^+^ currents ([Fig. 2*B*](#F0002){ref-type="fig"}). Interestingly, under these conditions N999S shows a paradoxical reduction in voltage sensitivity (slope, *z* = 0.95 ± 0.05) compared with WT (*z* = 1.56 ± 0.17; *P* = 0.0002, unpaired *t* test), despite its GOF effect on channel activity.

![Wild-type (WT) and N999S channel properties in physiological K^+^ and 10 μM Ca^2+^. *A*: representative macroscopic currents at 10-mV increments are shown together with the voltage-step protocol applied. *B*: conductance-voltage (*G-V*) curves of WT (*n* = 9) and N999S (*n* = 11) channels. *G* was normalized to the highest conductance calculated (*G*~max~). *C*: half-maximal voltage of activation (*V*~1/2~) individual values for WT and N999S channels (*P* \< 0.0001, 1-way ANOVA, Tukey post hoc test). *D*: activation time constant (τ~act~) vs. voltage for WT (*n* = 9) vs. N999S (*n* = 7). *Inset* shows representative activation traces of both channels at +100 mV. The N999S channels open significantly faster than the WT in a range between 0 and 100 mV (*P* \< 0.0001, 2-way ANOVA with Bonferroni post hoc). *E*: comparison of WT (*n* = 8) and N999S (*n* = 6) deactivation time constants (τ~deact~). N999S exhibits slower deactivation kinetics compared with WT in the range of −80 to −60 mV (*P* \< 0.05, 2-way ANOVAs with Bonferroni post hoc). *Inset* illustrates representative portion of the tail currents at −60 mV (2 s of the total 20-s deactivation protocol). *F*: action potential (AP) waveform voltage command (*inset*) and representative traces for WT and N999S AP-evoked currents. AP~peak~, AP peak current. *G*: normalized AP~peak~ level to the maximum steady-state current evoked by a standard voltage activation protocol (*I*~max~) (WT: 0.025, *n* = 9 and N999S: 0.465, *n* = 7; *P* \< 0.0001, 2-way ANOVA, Tukey post hoc test). *H*: normalized subthreshold current *I*~Subthr~ level at −50 mV to *I*~max~ (WT: 0.002 ± 0.0007 and N999S: 0.07 ± 0.0008); \*\*\*\**P* \< 0.0001, 1-way ANOVA, Tukey post hoc test.](z9k0022053530002){#F0002}

The effects of the mutation on activation of the channels was more pronounced under physiological K^+^-10 μM Ca^2+^. N999S channels opened 5 times faster (τ~act~) between 0 and +100 mV compared with WT ([Fig. 2*D*](#F0002){ref-type="fig"}), whereas N999S channels transitioned to the closed state (τ~deact~) \~4 times slower than the WT channels between −80 and −60 mV ([Fig. 2*E*](#F0002){ref-type="fig"}). These data corroborate a strong GOF phenotype under physiological K^+^ conditions, with changes in channel properties similar to those observed previously in symmetrical K^+^ and lower (1 μM) Ca^2+^.

The relevance of the N999S GOF phenotype in physiological K^+^-10 μM Ca^2+^ conditions was further probed by applying a dynamic voltage command obtained from a central neuron ([@B34]; [@B46]). Using this AP waveform as a voltage stimulus, we observed a massive increase of 18-fold in the AP-evoked current amplitude from N999S channels compared with WT ([Fig. 2](#F0002){ref-type="fig"}, *F* and *G*). Additionally, preceding the upstroke of the AP, the N999S subthreshold current is 35 times larger than WT measured at −50 mV ([Fig. 2*H*](#F0002){ref-type="fig"}). Considering these data, it is likely that the GOF properties conferred by N999S would affect BK currents in a typical neuronal context, both increasing the subthreshold K^+^ current that could oppose initiation of the AP as well as increasing the amount of K^+^ current evoked during an AP.

### N999S GOF activity compared to D434G channels. {#sec3-1-2}

To evaluate the degree of GOF activity for N999S, we compared it to the first identified and more extensively studied *KCNMA1* GOF mutation, D434G ([@B10]; [@B46]; [@B50]). Previous studies of the D434G mutation show a *V*~1/2~ shifted to negative potentials, faster activation, slower deactivation, an increase in open probability, and an increased Ca^2+^ sensitivity compared with the WT BK currents ([@B8]; [@B10]; [@B34]; [@B46]; [@B50]). Consistent with previous studies, in physiological K^+^ and 10 μM Ca^2+^ conditions ([@B46]), D434G had GOF current properties with a *V*~1/2~ of +8 ± 3.2 mV ([Fig. 3](#F0003){ref-type="fig"}, *A--C*). However, N999S currents were still 17 mV more shifted to negative potentials (*V*~1/2~ −8 ± 4.2 mV). Although activation of D434G was already faster than WT (at +30 mV WT τ~act~ = 7.8 ms vs. D434G τ~act~ = 2.1 ms; [Figs. 2*D*](#F0002){ref-type="fig"} and [3*D*](#F0003){ref-type="fig"}), activation of N999S was 3.5 times faster than D434G between 0 and 100 mV. Similarly, even though D434G channels already closed slower than WT (at −60 mV WT τ~deact~ = 1.2 ms vs. D434G τ~deact~ = 1.76 ms; [Figs. 2*E*](#F0002){ref-type="fig"} and [3*E*](#F0003){ref-type="fig"}), the τ~deact~ for N999S was still 4 times slower than D434G at −60 mV. Because N999S exceeds the GOF phenotype of D434G with respect to the voltage dependence of activation, and channels activate faster and deactivate slower, this suggests a greater potential for N999S to alter neuronal excitability.

![Comparison between N999S and D434G channel properties in physiological K^+^ and 10 μM Ca^2+^. *A*: representative macroscopic currents with the voltage-step protocol. *B*: conductance-voltage (*G-V*) relationships of N999S (*n* = 11) and D434G (*n* = 12) channels. The *G-V* curves are fitted by a Boltzmann function (solid line) with a half-maximal voltage of activation (*V*~1/2~) of −8 ± 4.2 mV for N999S and +8 ± 3.2 mV for D434G mutations. *G* was normalized to the highest conductance calculated (*G*~max~). *C*: individual *V*~1/2~ values for N999S and D434G are significantly different (\**P* = 0.01, 1-way ANOVA with Tukey post hoc). *D*: activation kinetics \[activation time constant (τ~act~)\] of N999S (*n* = 7) and D434G (*n* = 12) mutations. *Inset* corresponds to representative activation traces of both channels at +100 mV. The N999S channels open faster than D434G in the voltage range between 0 and 100 mV (*P* \< 0.0001, 2-way ANOVA with Bonferroni post hoc). *E*: deactivation kinetics \[deactivation time constant (τ~deact~)\] of N999S (*n* = 6) vs. D434G (*n* = 10). The N999S mutation has slower deactivation kinetics than the D434G mutation only at −60 mV (*P* \< 0.0001, 2-way ANOVA with Bonferroni post hoc). *Inset* illustrates a representative portion of the tail currents at −60 mV (2 s of the total 20-s deactivation protocol). *F*: voltage protocol and representative traces of N999S and D434G action potential (AP)-evoked current. AP~peak~, AP peak current. *G*: normalized AP~peak~ values to the maximum steady-state current evoked by a standard voltage activation protocol (*I*~max~) for both mutations. The amplitude of N999S (*n* = 7) current is 2 times larger than that of D434G (*n* = 12) (\*\*\*\**P* \< 0.0001, 1-way ANOVA with Tukey post hoc test).](z9k0022053530003){#F0003}

To test this, the range of voltages over which the differences between N999S and D434G were expressed was considered. The neuronal resting membrane potential is between −70 and −50 mV, whereas the peak of the AP happens between 10 and 50 mV, depending on the neuronal type ([@B2]). Because the differences in biophysical properties between N999S and D434G manifest in this range of voltages, we evaluated the AP-evoked BK currents generated by these two mutations. Although the AP-evoked current from D434G channels was already 9 times greater than WT ([Fig. 2](#F0002){ref-type="fig"}, *F* and *G*, and [Fig. 3](#F0003){ref-type="fig"}, *F* and *G*), the AP-evoked current generated by N999S channels was approximately twice as large as that of D434G. Thus the biophysical GOF alterations caused by the N999S mutation surpass D434G in the ability to generate larger AP-evoked currents, suggesting the potential for a distinct, and presumably stronger, GOF phenotype in vivo.

### Effect of second-site mutation R1128W. {#sec3-1-3}

One of the three patients described recently harbors a second de novo mutation, R1128W, in addition to N999S ([@B16]). To determine whether the N999S/R1128W double mutation presents a phenotype different from N999S alone, we evaluated the biophysical properties of N999S/R1128W double-mutant channels in symmetrical K^+^-1 μM Ca^2+^ and physiological K^+^-10 μM Ca^2+^ conditions ([Fig. 4*A*](#F0004){ref-type="fig"}). We observed no significant differences in the *V*~1/2~ between N999S and N999S/R1128W in both conditions ([Fig. 4](#F0004){ref-type="fig"}, *B* and *C*). Both types of channels exhibit the same activation and deactivation kinetics, with no significant differences between them ([Fig. 4](#F0004){ref-type="fig"}, *D* and *E*). Finally, when we evaluated the impact of the N999S/R1128W double mutation on the AP-evoked currents we observed no significant difference compared with the N999S mutation alone ([Fig. 4](#F0004){ref-type="fig"}, *F* and *G*). Thus we conclude that there is no additional phenotype in the N999S/R1128W double mutation, neither exacerbating nor mitigating the primary alteration produced by N999S. This finding agrees with the lack of additional symptoms in this patient compared with patients harboring N999S alone ([@B16]). However, it is still possible that the phenotype of N999S mutation masks a phenotype associated with the R1128W mutation alone that is not expressed under the conditions tested here.

![Effect of the R1128W mutation with N999S. *A*: representative macroscopic currents at +20-mV increments for 1 μM Ca^2+^ or +10 mV with 10 μM Ca^2+^ are depicted. *B*: conductance-voltage (*G-V*) relationships of N999S (*n* = 11) and N999S/R1128W (*n* = 7) channels in symmetrical K^+^ and 1 μM Ca^2+^ and physiological K^+^ and 10 μM Ca^2+^. *G* was normalized to the highest conductance calculated (*G*~max~). The N999S/R1128W half-maximal voltage of activation (*V*~1/2~) is +79 ± 1 mV in symmetrical K^+^-1 μM Ca^2+^ and −4 ± 6 mV in physiological K^+^-10 μM Ca^2+^. *C*: individual *V*~1/2~ values for N999S and N999S/R1128W are not statistically different \[*P* \> 0.05 (n.s.), 1-way ANOVA with Tukey post hoc test\]. *D* and *E*: activation \[*D*; activation time constant (τ~act~) N999S/R1128W *n* = 5 and N999S *n* = 7\] and deactivation \[*E*, deactivation time constant (τ~deact~) N999S/R1128W *n* = 5 and N999S *n* = 7\] kinetics of N999S and N999S/R1128W mutations. There is no significant difference in both kinetics in the entire range of voltages evaluated (*P* \> 0.05, 2-way ANOVA with Bonferroni post hoc). *F*: voltage protocol (*inset*) and representative traces of N999S and N999S/R1128W action potential (AP)-evoked current. AP~peak~, AP peak current. *G*: normalized AP~peak~ values for both mutations (N999S/R1128W *n* = 5 and N999S *n* = 7) show the same current amplitude, \[*P* \> 0.05 (n.s.), 1-way ANOVA with Tukey post hoc test\].](z9k0022053530004){#F0004}

### Effect of acetazolamide in N999S and WT BK channels. {#sec3-1-4}

Acetazolamide (ACTZ), an inhibitor of the enzyme carbonic anhydrase, is a drug widely used in epilepsy treatment ([@B35]; [@B43]). One of the three patients harboring the N999S mutation referred to in this study responded positively to the ACTZ treatment ([@B16]). However, in addition to the carbonic anhydrase mechanism, ACTZ has been reported to have a direct agonist effect on BK channels in skeletal muscle ([@B9]; [@B41]). Given the possibility of exacerbation of GOF activity by exposure to an agonist, which could worsen patient symptoms, we studied the effect of ACTZ on N999S and WT channels in the brain splice variant background. The protocol used consisted of a 20-ms depolarizing pulse at the N999S or WT channel's *V*~1/2~ every 5 s. After a 1-min baseline, 50 μM ACTZ was applied and the steady-state current sizes were evaluated ([Fig. 5](#F0005){ref-type="fig"}, *A* and *B*). The concentration of 50 μM was calculated as an estimation of the plasma concentration for an antiepileptic-dose treatment of 250 mg/day, with a clearance of 36.7 mL/min ([@B51]). Additionally, the concentration reported to activate BK channels in vitro ranged from 10 to 200 μM ([@B9]; [@B41]). First, we found no significant effect of ACTZ on the current magnitude for WT channels ([Fig. 5](#F0005){ref-type="fig"}, *A*, *C*, and *D*), establishing that ACTZ does not show agonist activity under these conditions. N999S channels also did not respond to ACTZ application, showing neither an increase in activity nor a difference compared with WT ([Fig. 5](#F0005){ref-type="fig"}, *B*, *E*, and *F*). As a perfusion control, the BK channel inhibitor paxilline (100 nM) was applied at the end of the experiments. Paxilline was able to inhibit 98% of WT and 95% of N999S BK currents from the patches (*P* \> 0.05, 1-way ANOVA). Reduction in paxilline's effect on N999S channels has been reported, but the effect was less in this study than previously observed ([@B25]). Taken together, this experiment demonstrates that ACTZ has no direct agonist effect on the WT splice variant used in this study and, furthermore, N999S channels do not differ from WT in their lack of response to ACTZ.

![Effect of acetazolamide (ACTZ) and paxilline on wild-type (WT) and N999S channels. *A* and *B*: representative experimental protocol (*left*) and current (*I*) level vs. time for WT (*A*) and N999S (*B*) channels. The black bar denotes application of 50 μM ACTZ to the patches, and the gray bar corresponds to application of 100 nM paxilline. *C* and *E*: individual current levels from each patch before ACTZ (30 s), after ACTZ (120 s), and after paxilline (Pax; 240 s) for WT (*n* = 6) and N999S (*n* = 9) channels. *D* and *F*: normalized data presented as % of the initial current (*I*~initial~). No significant differences were found for WT or N999S channels after 50 μM ACTZ \[*P* \> 0.05 (n.s.), paired *t* test\]. The reduction of the current due to paxilline application was significant (*P* \< 0.05, paired *t* test).](z9k0022053530005){#F0005}
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In this study, the properties of BK channels encoded by *KCNMA1* patient mutations associated with epilepsy and/or paroxysmal nonkinesigenic dyskinesia (PNKD) were investigated. Electrophysiological characterization of N999S, N999S/R1128W, and D434G BK currents demonstrated that each mutation manifests strong GOF properties on a brain splice variant background with AP stimuli compared with WT channels. Comparison of the currents revealed N999S to have greater effects on channel properties compared with the previously characterized D434G mutation, further shifting the voltage dependence of activation to hyperpolarized potentials and further speeding activation and slowing deactivation of the channels. We additionally showed that neither the second-site mutation R1128W nor the antiepileptic ACTZ exacerbated the primary N999S GOF current phenotype.

Interpretation of the effect of the mutations on BK current properties is qualified by the presence of a Myc tag at the NH~2~ terminus and a YFP tag inserted at the beginning of the RCK2 domain. However, the *V*~1/2~s produced by tagged and untagged WT channels with the same splice variant is similar at 0, 1, 10, and 100 μM Ca^2+^ ([@B34]), suggesting that the tags do not alter BK channel function. Additionally, the results here agree with other studies reporting D434G and N999S current properties using untagged channel variants, including the direction and order of magnitude of the *V*~1/2~ shift and the ∼3 times faster activation for D434G (activation was not studied previously for N999S) ([@B25]; [@B46]; [@B50]). Some minor variations in the magnitude of the *V*~1/2~ shifts between this and the other studies could be due to the different Ca^2+^ concentrations and splice variants used. Additionally, green fluorescent protein insertions at several positions in the linker between RCK1 and RCK2 do not show significant differences in the *V*~1/2~ values, either ([@B14]), suggesting that this region of the channel tolerates insertion of fluorescent proteins without substantial perturbations in the gating properties. Although small effects from the tags can become relevant in detailed biophysical characterization of these mutations, the consistency with other studies using WT and mutant untagged channels supports the comparative interpretation of the N999S and D434G current properties presented here.

The mechanism by which N999S alters BK channel activity is not fully elucidated by these data, but several lines of evidence suggest that this mutation primarily alters voltage-dependent gating. The similar magnitude of the *V*~1/2~ shift for N999S compared with WT in Ca^2+^-free conditions (data not shown), and at both 1 and 10 μM Ca^2+^, suggests no change over the Ca^2+^ gating mechanism. This observation is consistent with prior studies showing that mutations of the Ca^2+^-binding sites in the gating ring do not eliminate the increase in current conferred by N999S ([@B25]). Interestingly, at 10 μM Ca^2+^ a change in the slope of the *G-V* relationship was observed, suggesting a small effect on the voltage activation mechanism. Considering the distal location of N999S at the end of the COOH terminus ([Fig. 1*A*](#F0001){ref-type="fig"}), this change in slope could reflect an alteration in the allosteric gating mechanism through the VSD domain. The substitution of serine for asparagine, which retains the polar properties, could confer a new potential for phosphorylation at that residue. However, Netphos analysis does not show any consensus kinase site in this region with the mutation, suggesting that other properties distinguishing these residues factor into the differences. Interestingly, despite its distal localization in the primary amino acid sequence, the N999 residue is near the AC region that connects TM6 with the gating ring in the open-state BK channel crystal structure (*Aplysia* Slo1). This AC region is essential for coupling in the allosteric gating mechanism ([@B40]). The D434G mutation is also located in the AC region, but near the Ca^2+^-binding site of RCK1 ([Fig. 1*A*](#F0001){ref-type="fig"}), which, in contrast to N999S, is consistent with alteration of the Ca^2+^ gating mechanism by D434G ([@B25]; [@B46]; [@B50]). Even more distally located at the end of the COOH terminus, the R1128W mutation would result in a nonconservative loss of a positively charged arginine, replaced by the bulky hydrophobic tryptophan. However, R1128 is not resolved in the two crystal structures currently available ([@B40]; [@B52]), and little is known about the role of residues near R1128 in BK channel gating. Thus, despite the GOF nature of both the D434G and N999S mutations, the potentially distinct biophysical mechanisms produce a different magnitude of effect on BK current properties that is detectable under one type of reconstituted physiological condition. In this study, the N999S mutation clearly surpasses the D434G GOF phenotype, with a more negative *V*~1/2~ and faster activation and slower deactivation kinetics. These differences resulted in larger AP-evoked currents from N999S channels compared with D434G, yet patients harboring N999S, N999S/R1128W, and D434G GOF mutations share largely the same core symptoms of epilepsy and/or PNKD, suggesting a mechanistically similar effect on excitability in vivo.

On one hand, these core symptoms may actually be more variable when examined in detail. Closer scrutiny of patient phenotypes reveals there is variability in the prevalence and type of seizure and the prevalence of dyskinesia, both between D434G and N999S patients and also within each mutation group ([@B1]). The variability could stem from differences in the genetic backgrounds between patients, consistent with the de novo nature of the N999S mutations, but it is also observed in related individuals harboring the D434G mutation. Interestingly, some of the patients harboring the N999S mutations also present developmental delay and/or intellectual disability, a condition not reported for D434G patients ([@B1]). The possibility that distinct symptoms could be associated with each GOF mutation can be explored further as more patients are identified and reported with standardized diagnostic criteria.

On the other hand, it is possible that in the neuronal context these two GOF mutations produce more similar effects on BK currents than studies in heterologous cells reveal. The differences between the mutations in vivo could be reduced by coassembly with WT and accessory subunits, or at physiological temperatures and patterns of AP firing that were not tested in this study. These experiments were performed on homotetrameric channels because this represents the most controlled condition with which to directly compare the WT and mutant BK current types. However, patients harboring D434G and N999S are heterozygous ([@B10]; [@B16]; [@B25]), which leads to the possibility of BK channels composed of WT/N999S and WT/D434G heterotetramers that could potentially attenuate the GOF phenotype. At present, no information is available about the allele expression that could give clues about the stoichiometry of patient channels in native cells. Besides heterotetramerization, other possibilities that could reduce the difference between these two mutations in vivo include that the N999S and D434G mutations could produce different magnitude effects according to the splice variants expressed. Across tissues or between different neuronal subtypes, the distinct BK channel splice variants show differences in channel activity, Ca^2+^ sensitivity, activation and deactivation kinetics, and interaction with accessory subunits ([@B5]; [@B21]). However, the substantial shift in the voltage dependence of activation for N999S channels found in this study is similar to the 59-mV shift reported with a different BK channel splice variant ([@B25]), suggesting that the GOF effects are effectively conferred through at least some sequence variations in the BKα subunit. Other factors in the native neuronal context could also mitigate the phenotype and render N999S channels more similar to D434G or even closer to WT in their properties. One contributor to this possibility could be coexpression with an accessory subunit, such as the neuronal β4 subunit. β4 slows BK channel activation and deactivation and shifts the voltage dependence of activation, with a net effect of reducing AP-evoked BK current ([@B4]; [@B45]). Nevertheless, coexpression of N999S or D434G channels with β4 produces a effect on those currents similar to the effect on WT, with the mutant currents remaining left-shifted and faster activating compared with WT currents ([@B25]; [@B46]). For D434G + β4, this results in larger AP-evoked currents compared with WT ([@B46]). These studies suggest that inclusion of β4 in mutant channel complexes might not prevent either the increased current compared with WT or the increased current from N999S compared with D434G in vivo. Finally, firing patterns and ionic conditions different from those tested here could also serve to reduce differences between N999S and D434G. For example, under a train of APs a sustained elevation of intracellular Ca^2+^ could maximally activate both types of mutant channels and collapse the differences in evoked current between them. This was partly observed for D434G currents, where the difference compared with WT was reduced above 30 μM Ca^2+^ until it overlapped at 100 μM Ca^2+^ ([@B46]; [@B50]).

Because the N999S and N999S/R1128W mutations are associated with a high frequency of seizures and PNKD attacks in patients, it is important to understand under what conditions the mutations might express their most dramatic effects on excitability. Our data suggest two possible changes in membrane excitability associated with the mutations that could lead to alterations in neuronal activity. At the neuronal resting potential, between −70 and −50 mV, depending on the neuronal type ([@B2]), the voltage-activated Ca^2+^ channels have a significant open probability. This allows the local Ca^2+^ concentration to increase dynamically in a range between 1 and 50 μM Ca^2+^, which activates the BK channels ([@B7]; [@B13]; [@B26]; [@B32]). In neurons expressing BK channels with the N999S mutation, the first potential mechanism to change neuronal excitability would be via a decrease in firing due to increased subthreshold BK current. This increased subthreshold current would result from the significantly shifted voltage dependence of activation for N999S channels to more hyperpolarized potentials. Our results show that N999S channels are 35 times more active than WT at subthreshold potentials at 10 μΜ calcium. In this case, firing would decrease because it would be harder to exceed threshold, making triggering the AP more difficult. If this occurred in inhibitory neurons, the reduced activity could precipitate seizure. A second potential change in excitability could be produced by increased N999S current during the AP, when the threshold is surpassed. Under voltage clamp, AP-evoked currents from N999S channels were 18-fold larger at the peak compared with WT. This larger current could contribute to changing firing in either direction, depending on the amount of current activated during repolarization versus the afterhyperpolarization (AHP) ([@B6]; [@B30]). For example, in the simplest cases, firing would be expected to increase if N999S contributed predominantly to repolarizing current, whereas decreased firing could be obtained if the AHP were prolonged. Because of both the faster activation and the slower deactivation, it is likely that N999S channels would contribute to both phases, making the net effect on AP activity uncertain until defined within a specific neuronal context and firing pattern.

Finally, when seizure activity is provoked, the efficacy of drug treatment could be affected by the potential for off-target effects on ion channels such as BK. The widely used antiepileptic drug acetazolamide (ACTZ) ([@B35]; [@B43]) was administered to one of the three patients harboring the N999S mutations, showing a positive response ([@B16]). ACTZ has a direct effect on carbonic anhydrase and several off-target effects, but most notably it has also been previously reported as a direct agonist on skeletal muscle splice variant BK channels ([@B9]; [@B41]), raising the possibility that it would exacerbate GOF BK channel activity. However, our data show that ACTZ has no effect on either WT or N999S channels on the brain variant, suggesting that it would not exacerbate the pathogenicity of the GOF properties in vivo. Nevertheless, it is possible that this lack of agonist effect could be due to the different splice variant expressed in skeletal muscle cells, which differs from the variant in this study at alternate splice site 2 (STREX) and the sequence of exon 21 and intron 22 ([@B9]), or the lack of other channel components in the heterologous versus native cell context. However, since the N999S mutation already produces an increase in BK channel activity, any agonist effect of ACTZ is unlikely to be the mechanism causing the positive response in the patient.
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